InvestorsHub Logo
Followers 220
Posts 32381
Boards Moderated 1
Alias Born 08/28/2003

Re: aries4747 post# 2095

Wednesday, 03/27/2019 9:07:09 AM

Wednesday, March 27, 2019 9:07:09 AM

Post# of 3632
Precipio Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing
7:46 am ET March 27, 2019 (Globe Newswire) Print

Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has received the expected delisting determination from Nasdaq Staff. The Company has subsequently filed a request for a hearing before the Nasdaq Hearings Panel (the "Panel"), as management believes that it has strong basis for requesting the appeal. The process involves the Company requesting a compliance hearing within 7 days from the receipt of the delisting notification. Companies are typically scheduled for a hearing 30 to 45 days from the date of its request for a hearing, and the Hearing Panel typically issues a decision within 30 days of the hearing.

As informed by Nasdaq, the delisting of the company will be postponed pending a decision by the Hearing Panel - meaning the company shall remain listed on Nasdaq until the hearing takes place, and the Hearing Panel has issued a written decision.

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard's Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements," within the meaning of federal securities laws, including potential market opportunity, plans and prospects and other statements containing the words "anticipate," "intend," "may," "plan," "predict," "will," "would," "could," "should," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company's definitive proxy statement filed on May 29, 2018, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and on the Annual Report on Form 10-K for the year ended December 31, 2017 as well as the Company's prior filings and from time to time in the Company's subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Precipio Inquiries:
investors@precipiodx.com
+1-203-787-7888

https://ml.globenewswire.com/media/d80ae417-b29a-4736-afa2-0f5e3beae51b/small/prpo-logo-png.png
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PRPO News